Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons .
The effect of adjuvant and immunization schedule on the immunogenicity of HIV-1 envelope glycoprotein, MN rgp120, was optimized by using baboons. The novel adjuvant QS21 elicited earlier seroconversion than alum adjuvant, and the antibody titers to MN rgp120 for animals treated with QS21 were significantly greater than the titers obtained in animals treated with alum. The use of QS21 shifted the dose-response curve, resulting in less MN rgp120 required to achieve equivalent titers to those in the alum formulations. The in vitro virus neutralizing (VN) titers from animals treated with QS21 were 3- to 10-fold higher than with alum. The data presented herein point to the superiority of QS21 as adjuvant in primates for MN rgp120.
Powell
M F
MF
Department of Pharmaceutical Research and Development, Genentech, Inc., South San Francisco, California 94080.
Cleland
J L
JL
Eastman
D J
DJ
Lim
A
A
Murthy
K
K
Newman
M J
MJ
Nunberg
J H
JH
Weissburg
R P
RP
Vennari
J C
JC
Wrin
T
T
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000534:Alum Compounds / Q000008:administration & dosage; D000818:Animals; D015483:HIV Antibodies / Q000096:biosynthesis; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage / Q000276:immunology; D006679:HIV Seropositivity / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D066298:In Vitro Techniques; D009500:Neutralization Tests; D010215:Papio; D012503:Saponins / Q000008:administration & dosage / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D012503:Saponins; D014614:Vaccines, Synthetic; C041524:aluminum sulfate; C078785:saponin QA-21V1